Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, Leitner T, Gaschen B, Theiler J, Paredes R, Su Z, Hughes MD, Gulick RM, Greaves W, Coakley E, Flexner C, Nusbaum C, Kuritzkes DR.

PLoS One. 2009 May 25;4(5):e5683. doi: 10.1371/journal.pone.0005683.

2.

Detection of HIV-1 CXCR4 tropism and resistance in treatment experienced subjects receiving CCR5 antagonist-Vicriviroc.

McNicholas P, Vilchez RA, Greaves W, Kumar S, Onyebuchi C, Black T, Strizki JM.

J Clin Virol. 2012 Oct;55(2):134-9. doi: 10.1016/j.jcv.2012.06.021. Epub 2012 Jul 21.

PMID:
22824230
3.

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc.

Berro R, Klasse PJ, Jakobsen MR, Gorry PR, Moore JP, Sanders RW.

Virology. 2012 Jun 5;427(2):158-65. doi: 10.1016/j.virol.2012.02.006. Epub 2012 Mar 16. Erratum in: Virology. 2012 Jun 20;428(1):76. Jakobsen, Martin R [added]; Gorry, Paul R [added].

4.

Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.

Henrich TJ, Tsibris AM, Lewine NR, Konstantinidis I, Leopold KE, Sagar M, Kuritzkes DR.

J Acquir Immune Defic Syndr. 2010 Dec;55(4):420-7. doi: 10.1097/QAI.0b013e3181f25574.

5.

HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.

Putcharoen O, Lee SH, Henrich TJ, Hu Z, Vanichanan J, Coakley E, Greaves W, Gulick RM, Kuritzkes DR, Tsibris AM.

J Virol. 2012 Jan;86(2):1119-28. doi: 10.1128/JVI.06421-11. Epub 2011 Nov 16.

6.

A maraviroc-resistant HIV-1 with narrow cross-resistance to other CCR5 antagonists depends on both N-terminal and extracellular loop domains of drug-bound CCR5.

Tilton JC, Wilen CB, Didigu CA, Sinha R, Harrison JE, Agrawal-Gamse C, Henning EA, Bushman FD, Martin JN, Deeks SG, Doms RW.

J Virol. 2010 Oct;84(20):10863-76. doi: 10.1128/JVI.01109-10. Epub 2010 Aug 11.

7.

Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities.

Pugach P, Ray N, Klasse PJ, Ketas TJ, Michael E, Doms RW, Lee B, Moore JP.

Virology. 2009 May 10;387(2):296-302. doi: 10.1016/j.virol.2009.02.044. Epub 2009 Mar 20.

8.

In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.

Tsibris AM, Sagar M, Gulick RM, Su Z, Hughes M, Greaves W, Subramanian M, Flexner C, Giguel F, Leopold KE, Coakley E, Kuritzkes DR.

J Virol. 2008 Aug;82(16):8210-4. doi: 10.1128/JVI.00444-08. Epub 2008 May 21.

9.

Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.

Jiang X, Feyertag F, Meehan CJ, McCormack GP, Travers SA, Craig C, Westby M, Lewis M, Robertson DL.

J Virol. 2015 Nov;89(22):11457-72. doi: 10.1128/JVI.01384-15. Epub 2015 Sep 2.

10.

Detection of inferred CCR5- and CXCR4-using HIV-1 variants and evolutionary intermediates using ultra-deep pyrosequencing.

Bunnik EM, Swenson LC, Edo-Matas D, Huang W, Dong W, Frantzell A, Petropoulos CJ, Coakley E, Schuitemaker H, Harrigan PR, van 't Wout AB.

PLoS Pathog. 2011 Jun;7(6):e1002106. doi: 10.1371/journal.ppat.1002106. Epub 2011 Jun 23.

11.

Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).

McNicholas PM, Mann PA, Wojcik L, Qiu P, Lee E, McCarthy M, Shen J, Black TA, Strizki JM.

J Acquir Immune Defic Syndr. 2011 Mar 1;56(3):222-9. doi: 10.1097/QAI.0b013e3181ff63ee.

PMID:
21209592
12.

Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.

Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR.

J Virol. 2012 Jun;86(12):6416-26. doi: 10.1128/JVI.00286-12. Epub 2012 Apr 4.

13.

Pharmacokinetic/pharmacodynamic modeling of the antiretroviral activity of the CCR5 antagonist Vicriviroc in treatment experienced HIV-infected subjects (ACTG protocol 5211).

Crawford KW, Li C, Keung A, Su Z, Hughes MD, Greaves W, Kuritzkes D, Gulick R, Flexner C; ACTG A5211 Study Team.

J Acquir Immune Defic Syndr. 2010 Apr;53(5):598-605. doi: 10.1097/QAI.0b013e3181c9caac.

14.

Genotypic analysis of the V3 region of HIV from virologic nonresponders to maraviroc-containing regimens reveals distinct patterns of failure.

Swenson LC, Chui CK, Brumme CJ, Chan D, Woods CK, Mo T, Dong W, Chapman D, Lewis M, Demarest JF, James I, Portsmouth S, Goodrich J, Heera J, Valdez H, Harrigan PR.

Antimicrob Agents Chemother. 2013 Dec;57(12):6122-30. doi: 10.1128/AAC.01534-13. Epub 2013 Sep 30.

15.

A pi├Ęce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.

Moore JP, Kuritzkes DR.

Curr Opin HIV AIDS. 2009 Mar;4(2):118-24. doi: 10.1097/COH.0b013e3283223d46. Review.

16.

Genotypic inference of HIV-1 tropism using population-based sequencing of V3.

McGovern RA, Harrigan PR, Swenson LC.

J Vis Exp. 2010 Dec 27;(46). pii: 2531. doi: 10.3791/2531.

17.

Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing.

Archer J, Braverman MS, Taillon BE, Desany B, James I, Harrigan PR, Lewis M, Robertson DL.

AIDS. 2009 Jun 19;23(10):1209-18. doi: 10.1097/QAD.0b013e32832b4399.

18.

Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.

Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT, Wolinsky SM, Moore JP.

J Virol. 2004 Mar;78(6):2790-807. Erratum in: J Virol. 2005 Jun;78(12):6706.

19.

Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.

McGovern RA, Symons J, Poon AF, Harrigan PR, van Lelyveld SF, Hoepelman AI, van Ham PM, Dong W, Wensing AM, Nijhuis M.

J Antimicrob Chemother. 2013 Sep;68(9):2007-14. doi: 10.1093/jac/dkt153. Epub 2013 May 14.

PMID:
23677920
20.

Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.

Anastassopoulou CG, Ketas TJ, Depetris RS, Thomas AM, Klasse PJ, Moore JP.

Virology. 2011 Apr 25;413(1):47-59. doi: 10.1016/j.virol.2010.12.052. Epub 2011 Feb 26.

Supplemental Content

Support Center